Navigation Links
Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say
Date:4/29/2010

PHILADELPHIA - Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

In this study, the viral vector, or missile that carries the genetic material designed to correct a DNA mutation, was not intended to treat a disease but to demonstrate through the use of a fluorescent protein that a safe and effective viral cocktail could be delivered inside rod cells.

The next major challenge that vision researchers face is to target these photoreceptor cells for treatment, as the majority of retinal degenerative diseases are caused by mutations that damage these cells. Photoreceptors are the cells in the retina responsible for capturing light and transforming it into an electrical signal that will be interpreted by the brain.

A consortium of researchers from Penn and the University of Florida used a specific adeno-associated virus, AAV2/5, to carry the gene of a green fluorescent protein. The scientists tested whether three different promoters, pieces of DNA that play the role of a switch, could turn on the production of the green fluorescent protein in rods in dogs. Two of the three viral cocktails were able to turn on the production of the green fluorescent protein specifically in rods, while the third viral cocktail targeted rods, cones and other retinal cells; however only the proper concentration of each viral vector proved to be just right. Efficient and specific rod transduction, together with preservation of retinal structure, was achieved with both mOP and hGRK1 promoters when viral titers in the order of 1011 vg/ml were used.

"Now that we've demonstrated this type of delivery can be accomplished, " said William A. Beltran, assistant professor of ophthalmology at Penn's School of Veterinary Medicine and director of the study, "the next step is to target common rod degenerations using canine models that mimic the human diseases. The delivery of a viral vector, coupled with a rod-specific promoter is likely to be the safest and most efficient approach to correct diseases such as X-linked and autosomal dominant retinitis pigmentosa, both of which lead to complete blindness."

A form of childhood blindness called RPE65-Leber's congenital amaurosis, LCA, is the first and to this date the only inherited retinal disease for which corrective gene therapy is currently being tested in three on-going clinical trials. This treatment was first developed and perfected in dogs by some of the scientists who participated in the present study before its use in human patients.

The study appears in the current issue of the Journal of Gene Therapy.


'/>"/>

Contact: Jordan Reese
jreese@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert  

Related biology news :

1. Smoking during radiation therapy for head and neck cancers linked to poorer outcomes
2. JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes
3. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
4. Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy
5. Gene therapy cures canines of inherited form of day blindness, Penn veterinary researchers say
6. Exercise therapy for low back pain
7. Making the blind see: Gene therapy restores vision in mice
8. New cancer therapy may fight cardiovascular disease
9. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. Hormone therapy for food poisoning bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):
(Date:8/21/2017)... (PRWEB) , ... August 20, 2017 , ... ... Journal of Biomedical Optics (JBO) starting 1 January 2018. The journal is published ... Biomedical Optics publishes papers on the use of modern optical technology for improved ...
(Date:8/21/2017)... ... August 21, 2017 , ... The team at ... webinar, in which attendees will learn about the assembly and topological architecture of ... an overview of the development and validation of new high-quality recombinant monoclonal antibodies, ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... and personalized medicine, today announced the launch of a new breast cancer monitoring ... study’s goal is to evaluate the potential for early detection of recurrent breast ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar ... has secured $2M in funding from an impressive group of investors, including Rev1 ... Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering ...
Breaking Biology Technology: